Core Viewpoint - Belite Bio, Inc has announced a public offering of 2,272,727 American Depositary Shares (ADSs) at a price of $154.00 per ADS, aiming to raise approximately $350 million for commercialization and pipeline development [1][2]. Group 1: Offering Details - The public offering consists of 2,272,727 ADSs priced at $154.00 each, with an additional option for underwriters to purchase up to 340,909 more ADSs [1]. - The expected gross proceeds from the offering are approximately $350 million before deducting underwriting discounts and commissions [1]. - The closing of the offering is anticipated to occur around December 3, 2025, pending customary closing conditions [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be allocated for commercialization preparation, including building an in-house commercialization team and establishing sales networks [2]. - Funds will also be used for the development and expansion of the company's drug pipeline [2]. - Additional proceeds will support working capital and other general corporate purposes [2]. Group 3: Company Overview - Belite Bio is focused on developing novel therapeutics for degenerative retinal diseases with significant unmet medical needs, such as Stargardt disease type 1 and geographic atrophy in advanced dry age-related macular degeneration [6]. - The company's lead candidate, Tinlarebant, is an oral therapy aimed at reducing bisretinoid toxins in the eye and has completed a Phase 3 trial in adolescent STGD1 subjects [6].

TOKYO, Dec. 1, 2025 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito) today announced that new data on anti-tau antibody etalanetug (development code: E2814) was presented at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference. Etalanetug is designed to bind to the microtubule- binding region (MTBR) of tau protein and prevent the seeding and propagation of tau pathology. Anti-tau therapeutic antibody, etalanetug, reduces the novel biomarker plasma eMTBR-tau243 in patien ...

Core Viewpoint - The Trump administration is supporting Bayer's request to the U.S. Supreme Court to limit the number of lawsuits alleging that its Roundup weedkiller causes cancer [1] Group 1 - Bayer is facing thousands of lawsuits related to its Roundup product, which claims it causes cancer [1] - The administration's backing may influence the Supreme Court's decision on whether to hear Bayer's case [1] - The outcome of this legal battle could have significant implications for Bayer's financial liabilities and reputation in the agricultural sector [1]

"In biotech securities cases, the core issue is often whether the company was accurately representing its data and trial design," said Reed Kathrein, the Hagens Berman partner leading the litigation. "The suit alleges that aTyr concealed material adverse facts concerning Efzofitimod's capability to allow a patient to completely taper their steroid usage—a key measure of efficacy—while emphasizing a multi-billion- dollar market. We are scrutinizing whether these prior statements about the drug's prospects cr ...

Chinese vaccine makers are caught in a steep downturn, as intensifying competition pushes prices lower and erodes profits, underscoring the far-reaching deflationary pressure across the world’s second-largest economy https://t.co/gHU1UhbK1g ...

Pelthos Pharmaceuticals ( PTHS ) is a commercial-stage company with a recently launched lead drug, Zelsuvmi. Zelsuvmi is the first at home FDA approved drug for the treatment for molluscum contagiosum. It was approved by the FDA inI am a long-term investor focused on growth markets, AI and biotech opportunities in my more volatile portfolio. I try to look for undervalued and under-the-radar stocks with serious potential and good scientific or other background. My ambition here is to cover stocks with consid ...

NEW YORK, Dec. 01, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) between February 21, 2025 and August 28, 2025, both dates inclusive (the “Class Period”), of the important January 9, 2026 lead plaintiff deadline in the securities class action first filed by the Firm. SO WHAT: If you purchased Telix securities during the Class Period you may be entitled to compensation without payment of any out o ...

Key TakeawaysU.S. Treasury Secretary Bessent announced a federal investigation into allegations that Minnesota tax dollars may have been diverted to the terrorist organization Al-Shabaab.Shanghai Bao Pharmaceuticals has launched a global offering of 37.9 million H-shares, signaling a significant move for the biotech firm on the Hong Kong Stock Exchange.Apple (AAPL) is set for a major leadership transition in its Artificial Intelligence division, with AI Chief John Giannandrea retiring in Spring 2026 and a n ...

The U.S. stock market commenced December on a subdued note, with major indexes retreating on Monday, December 1st, 2025, as investors recalibrated their risk appetite following a strong close to the previous week. A broad pullback was observed across various sectors, notably in technology and cryptocurrency-related equities, driven by a confluence of factors including rising bond yields and hints of a potential interest rate hike from the Bank of Japan. This downward movement marks a cautious start to the f ...

Shelby Knowles / Bloomberg / Getty Images Close Key Takeaways Eli Lilly (LLY) said Monday that it's lowering the price of its popular weight-loss drug Zepbound, about a month after striking a deal with the Trump administration to lower drug costs. The company said the price for a once-a-month single vial purchased through its LillyDirect digital health care platform will go down $50 for the 2.5-, 7.5-, 10-, 12.5-, and 15-milligram doses, and $100 for the 5-milligram dose. The prices range from $299 for the ...